National and Kapodistrian University of Athens
Η επίδραση της ερυθροποιητίνης και της L- καρνιτίνης στην αναιμία των αιμοκαθαιρομένων
Abstract
dc:descriptionIt is now evident that the most important factor causing anemia in patients with chronic renal failure is the decrease in Erythropoietin (EPO) secretion by the diseased kidneys. Another causal factor that may contribute to the etiology of renal anemia is the decrease of red blood cell half-life. This occurred due to the impact of circulating uremic toxic substances and carnitine deficiency, which usually is observed in dialysis patients. In this sense, many investigators have demonstrated that L- carnitine supplementation to renal patients undergoing hemodialysis, correct EPO resistance or reduce the recombinant human erythropoietin (rhuEPO) dose needed to achieve a desired hematocrit level. The purpose of present study is to demonstrate whether L- carnitine supplementation to hemodialysed patients treated with rhuEPO could further improve their hematologic status, also leading to a reduction in the rhuEPO requirements for achieving target- hematocrit. Also it aims to estimate the cost- benefit of the reduction of rhuEPO requirements. Materials and Methods: The sample of the study comprised 57 patients (32 men, 25 women) with end stage renal disease and their age ranging from 18-79 years (mean age 50 ± 16,9 years). Patients were studied for 12 months. For first six months, they were under rhuEPO maintenance treatment and various laboratory parameters were measured. For last six months, they received L- carnitine supplementation (1 g L- carnitine iv every dialysis session). Globular osmotic fragility, serum total and free carnitine levels and endogenous EPO levels in plasma were also measured at the onset, the middle and the end of this period. Results: L - carnitine promoted a 14,8% reduction in rhuEPO requirements (7947,4 ± 4336 U/Wk vs 6771,9 ± 4570,9 U/Wk, P = 0,012) for patients undergoing chronic hemodialysis. Globular osmotic fragility (P = 0,8) and endogenous EPO levels (P = 0,34) remaining unchanged and thus not accounting for carnitine effect on anemia. Also hematocrit levels were stabilized next to target hematocrit levels. Conclusions: L - carnitine treatment promoted a marked reduction in rhuEPO requirements which was related neither to higher endogenous EPO secretion by the patients’ kidney nor to any improvement in red blood cell membrane resistance. It is possible that L - carnitine deficiency might promote EPO resistance. So L - carnitine supplementation to patients undergoing chronic hemodialysis, correct EPO resistance, thus lowering the cost of dialytic treatment about 8,72 Euro per week and per patient
Degree
thesis:*- Grantor dc:publisher
- National and Kapodistrian University of Athens
- Year dc:date
- 2002
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Paikopoulou, Dimitra
- Παϊκοπούλου, Δήμητρα
Subjects
dc:subject × 12Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/21011